PULFAK MAREK CVI+HVT – Live Frozen Vaccine

Marek’s disease remains one of the most serious threats to industrial poultry, causing tumor formation and high mortality, leading to catastrophic economic losses. For early and effective herd protection, Zoetis developed the PULFAK MAREK CVI+HVT live frozen vaccine. The uniqueness of the product lies in its combination of two highly immunogenic strains, providing comprehensive biological protection for poultry in all types of production systems.

The main advantage of PULFAK MAREK CVI+HVT for large incubators is the ability to protect birds before they come into contact with the external environment. Each vaccine dose contains optimal concentrations of Marek’s disease virus (≥ 10⁴⁶ PFU) and turkey herpesvirus (≥ 9⁹² PFU). The vaccine is officially approved for subcutaneous administration to chicks within the first hours of life and for the innovative in-ovo inoculation method into the amniotic cavity of embryos on days 18–19 of incubation. This allows full automation of the vaccination process and guarantees accurate dosing for each bird.

Implementing PULFAK MAREK CVI+HVT in your farm’s veterinary protocol establishes a strategic barrier against one of the most dangerous poultry infections. Using this proven world-class vaccine ensures high survivability throughout the productive period. Choosing PULFAK MAREK CVI+HVT is an investment in biosecurity and long-term profitability, ensuring stable health and productivity of your flock.